CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies Meeting Abstract
| Authors: | Tannir, N. M.; Agarwal, N.; Porta, C.; Lawrence, N. J.; Motzer, R. J.; Lee, R. J.; Jain, R. K.; Davis, N. B.; Appleman, L. J.; Goodman, O. B.; Stadler, W. M.; Gandhi, S. G.; Geynisman, D. M.; Iacovelli, R.; Mellado, B.; Figlin, R. A.; Powles, T.; Akella, L. V.; Orford, K. W.; Escudier, B. |
| Abstract Title: | CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120602250 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.4501 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4501 -- Source: Wos |
